Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
+0.10 (5.24%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.90 - 2.05
52 week 1.61 - 3.57
Open 1.93
Vol / Avg. 319,118.00/119,290.00
Mkt cap 44.38M
P/E     -
Div/yield     -
EPS -1.13
Shares 23.24M
Beta 1.66
Inst. own 11%
Nov 5, 2015
Q3 2015 Celsion Corp Earnings Call
Nov 5, 2015
Q3 2015 Celsion Corp Earnings Release
Sep 9, 2015
Celsion Corp at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -3413.93% -5098.85%
Operating margin -3167.33% -4900.25%
EBITD margin - -4592.12%
Return on average assets -30.01% -45.38%
Return on average equity -63.17% -79.24%
Employees 28 -
CDP Score - -


997 Lenox Dr Ste 100
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Celsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters